Trial reportEndocrine2016
Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.
Trial report in Endocrine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Osilodrostat treatment in patients with Cushing's disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4).Endocrine journal · 2024Trial
- Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.European journal of endocrinology · 2020Trial
- "Feeding the Rhythm"-Effects of Food and Nutrients on Daily Cortisol Secretion: From Molecular Mechanisms to Clinical Impact.International journal of molecular sciences · 2025Review
- Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome.The Journal of clinical endocrinology and metabolism · 2025Article
- Real-life data on pasireotide in monotherapy or combined in active Cushing's disease.Frontiers in endocrinology · 2025Article
- Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol.Journal of the Endocrine Society · 2024Article
- An individualized approach to the management of Cushing disease.Nature reviews. Endocrinology · 2023Review
- Complications and mortality of Cushing's disease: report on data collected over a 20-year period at a referral centre.Pituitary · 2023Article
- Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples.Pituitary · 2022Review
- Approach to the Patient Treated with Steroidogenesis Inhibitors.The Journal of clinical endocrinology and metabolism · 2021Article
- Cortisol Measurements in Cushing's Syndrome: Immunoassay or Mass Spectrometry?Annals of laboratory medicine · 2020Review
- Cushing's Disease.Journal of clinical medicine · 2019Review
- Hypercortisolemia Recurrence in Cushing's Disease; a Diagnostic Challenge.Frontiers in endocrinology · 2019Review
- Metyrapone treatment in Cushing's syndrome: a real-life study.Endocrine · 2018Article
- Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.Endocrine · 2018Article
- A Review of Selected Studies That Determine the Physical and Chemical Properties of Saliva in the Field of Dental Treatment.BioMed research international · 2018Review
- Pituitary-Directed Therapies for Cushing's Disease.Frontiers in endocrinology · 2018Review
- Cyclical Cushing's: how best to catch the ups and downs.BMJ case reports · 2017Article
- Update on medical treatment for Cushing's disease.Clinical diabetes and endocrinology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Measuring salivary cortisol is a simple, convenient and accurate technique with potential value in monitoring patients with hypercortisolism. This analysis reports changes in late-night salivary cortisol (LNSC) during a 12-month, multicentre, Phase III study of patients with Cushing's disease who were randomized to pasireotide 600 or 900 μg sc bid. LNSC assessment was an exploratory objective based on a single, optional measurement at midnight ± 1 h on the same day as one of the 24-h urinary free cortisol (UFC) measurements. Of 162 enrolled patients, baseline LNSC was measured in 93. Sixty-seven patients had levels above the upper limit of normal (ULN); median baseline levels were 19.7 and 20.7 nmol/L in the groups subsequently randomized to 600 μg (n = 40) and 900 μg (n = 27), respectively. Median LNSC levels decreased from baseline to month 12; median changes in patients who had baseline LNSC > ULN in the 600 and 900 μg groups were -13.4 nmol/L (-52.6 %; n = 19) and -11.8 nmol/L (-56.1 %; n = 14), respectively. LNSC normalized at months 6 and 12 in 25/67 (37.3 %) and 13/67 (19.4 %) patients, respectively; 10/25 and 8/13 patients also had normalized UFC, and 7/25 and 4/13 had partial UFC control (UFC > ULN and ≥50 % decrease from baseline). There was a moderate correlation (r = 0.55) on the log scale between individual patient LNSC and UFC values when all time points were pooled. Pasireotide decreased LNSC levels during 12 months of treatment. Salivary cortisol may be a simple, convenient biomarker for assessing treatment response in patients with Cushing's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.